Companies

enGene Therapeutics Inc. (ENGN) SEC filings

CIK 0001980845 · Biological Products, (No Diagnostic Substances) (SIC 2836) · Nasdaq, Nasdaq · incorporated in Z4 · fiscal year ends 10/31

Annual financials (from the company's own XBRL in its 10-K filings)

FY2025FY2024FY2023
Net income (USD)-117.3 M-99.9 M-24.5 M
Diluted EPS (USD/shares)2.29151.2244.3

Latest filings

FiledFormDescriptionPeriod
2026-09-24442026-09-22
2026-09-0810-Q10-Q2026-07-31
2026-09-088-K8-K items 2.02,9.012026-09-08
2026-08-14SCHEDULE 13G/ASCHEDULE 13G/A
2026-08-14SCHEDULE 13G/ASCHEDULE 13G/A
2026-08-14SCHEDULE 13G/ASCHEDULE 13G/A
2026-08-13SCHEDULE 13G/ASCHEDULE 13G/A
2026-08-12SCHEDULE 13G/ASCHEDULE 13G/A
2026-08-118-K8-K items 8.01,9.012026-08-11
2026-07-22332026-07-16
2026-07-22332026-07-16
2026-07-22SCHEDULE 13GSCHEDULE 13G
2026-07-178-K8-K items 7.01,9.012026-07-17
2026-07-168-K8-K items 5.02,7.01,9.012026-07-15
2026-06-188-K/A8-K/A items 2.05,5.022026-06-16
2026-06-17442026-06-16
2026-06-17442026-06-16
2026-06-17442026-06-16
2026-06-17442026-06-16
2026-06-17442026-06-16
2026-06-17442026-06-16
2026-06-17442026-06-16
2026-06-17442026-06-16
2026-06-1510-Q10-Q2026-04-30
2026-06-158-K8-K items 2.02,2.05,5.02,7.01,8.01,9.012026-06-13

Forms on file (last 1,000): 4 65, 8-K 44, 3 31, SCHEDULE 13G/A 18, 424B3 13, CORRESP 11, 10-Q 9, SC 13G 9. Source: SEC EDGAR, as filed; this page is public data and not investment advice.

For software and AI agents: the same data as JSON, per call, no account: GET https://store.agentexchange.work/gw/filings/company?ticker=ENGN (0.002 USD), /gw/filings/filings?ticker=ENGN&form=8-K, /gw/filings/facts?ticker=ENGN&concept=Revenues, full-text /gw/filings/search?q=.... Pay per call in USDC (x402) or with a 19 USD card key for 1,000 calls. Catalogue · llms.txt

Updated from EDGAR within 30 minutes of a filing. Agent Exchange